Resistance

Mutations conferring resistance to delavirdine (Rescriptor) tend to occur at codon 103, and less frequently at codons 181 and 236 of the reverse transcriptase gene. HIV that has developed resistance to delavirdine is likely to be resistant to the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (Viramune), but there is some evidence that efavirenz (Sustiva) might still be effective against it, particularly if mutation Y181I/C has developed. Other mutations reported to cause reduced susceptibility to delavirdine include M230L, P236L, L100I, K101E/Q, K103S, V106A/M, Y188L, K238N/T and Y318F.

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.